Profile of maraviroc: a CCR5 antagonist in the management of treatment-experienced HIV patients

Thore LorenzenIFI Institute for Interdisciplinary Medicine, Hamburg, GermanyAbstract: Maraviroc is the first and, so far, the only licensed representative of the class of chemokine receptor type 5 (CCR5) inhibitors used for the treatment of human immunodeficiency virus (HIV) infection. Its safety an...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autor principal: Thore Lorenzen
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2010
Materias:
Acceso en línea:https://doaj.org/article/905b7ba498134757a0babd806097faed
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!